Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain | 22 | 2024 | 202 | 3.520 |
Why?
|
| Alzheimer Disease | 27 | 2024 | 250 | 3.420 |
Why?
|
| Aging | 15 | 2019 | 204 | 2.170 |
Why?
|
| Cognition Disorders | 13 | 2018 | 175 | 1.860 |
Why?
|
| Cognition | 13 | 2024 | 220 | 1.850 |
Why?
|
| DNA-Binding Proteins | 8 | 2019 | 69 | 1.610 |
Why?
|
| Aged, 80 and over | 35 | 2024 | 567 | 1.560 |
Why?
|
| Aged | 37 | 2024 | 956 | 1.480 |
Why?
|
| Male | 42 | 2024 | 1860 | 1.470 |
Why?
|
| Female | 41 | 2024 | 1724 | 1.430 |
Why?
|
| Humans | 47 | 2024 | 2957 | 1.280 |
Why?
|
| Memory Disorders | 3 | 2018 | 33 | 1.070 |
Why?
|
| TDP-43 Proteinopathies | 3 | 2017 | 12 | 1.030 |
Why?
|
| Cognitive Dysfunction | 8 | 2019 | 165 | 1.000 |
Why?
|
| Cerebral Amyloid Angiopathy | 3 | 2015 | 17 | 0.970 |
Why?
|
| Cohort Studies | 18 | 2024 | 233 | 0.930 |
Why?
|
| Dementia | 6 | 2018 | 73 | 0.930 |
Why?
|
| Brain Infarction | 3 | 2018 | 20 | 0.800 |
Why?
|
| Neuropsychological Tests | 15 | 2019 | 238 | 0.800 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2017 | 92 | 0.700 |
Why?
|
| Longitudinal Studies | 16 | 2019 | 260 | 0.690 |
Why?
|
| Memory | 4 | 2018 | 48 | 0.660 |
Why?
|
| Hippocampus | 4 | 2019 | 41 | 0.630 |
Why?
|
| Apolipoprotein E4 | 3 | 2016 | 76 | 0.610 |
Why?
|
| Plaque, Amyloid | 4 | 2016 | 18 | 0.540 |
Why?
|
| Genome-Wide Association Study | 6 | 2020 | 46 | 0.450 |
Why?
|
| Neurofibrillary Tangles | 4 | 2017 | 24 | 0.410 |
Why?
|
| Parkinson Disease | 4 | 2017 | 65 | 0.400 |
Why?
|
| Amyloid beta-Peptides | 5 | 2024 | 28 | 0.390 |
Why?
|
| DNA Methylation | 4 | 2017 | 44 | 0.380 |
Why?
|
| Cerebral Infarction | 4 | 2015 | 18 | 0.380 |
Why?
|
| Neurodegenerative Diseases | 3 | 2018 | 34 | 0.350 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 46 | 0.350 |
Why?
|
| Genotype | 8 | 2017 | 85 | 0.320 |
Why?
|
| Folic Acid | 3 | 2006 | 10 | 0.300 |
Why?
|
| Apolipoproteins E | 3 | 2017 | 34 | 0.300 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 97 | 0.290 |
Why?
|
| Neuropathology | 3 | 2018 | 16 | 0.290 |
Why?
|
| Vitamin B 12 | 2 | 2006 | 8 | 0.280 |
Why?
|
| Dietary Supplements | 2 | 2006 | 16 | 0.280 |
Why?
|
| Lewy Bodies | 6 | 2019 | 37 | 0.280 |
Why?
|
| Logistic Models | 3 | 2017 | 60 | 0.270 |
Why?
|
| Alleles | 6 | 2017 | 65 | 0.270 |
Why?
|
| Autopsy | 5 | 2019 | 39 | 0.260 |
Why?
|
| Parkinsonian Disorders | 2 | 2017 | 24 | 0.240 |
Why?
|
| Receptors, Immunologic | 2 | 2017 | 3 | 0.240 |
Why?
|
| Membrane Glycoproteins | 2 | 2017 | 15 | 0.240 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2017 | 13 | 0.240 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 23 | 0.240 |
Why?
|
| Membrane Transport Proteins | 2 | 2017 | 22 | 0.240 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2006 | 6 | 0.240 |
Why?
|
| Disease Progression | 5 | 2019 | 99 | 0.230 |
Why?
|
| Substantia Nigra | 1 | 2006 | 12 | 0.230 |
Why?
|
| Stroke | 2 | 2016 | 49 | 0.230 |
Why?
|
| Food, Fortified | 1 | 2005 | 3 | 0.220 |
Why?
|
| Risk Factors | 9 | 2017 | 275 | 0.220 |
Why?
|
| Genetic Loci | 2 | 2014 | 13 | 0.210 |
Why?
|
| Sclerosis | 4 | 2019 | 25 | 0.210 |
Why?
|
| Healthy Lifestyle | 1 | 2024 | 13 | 0.210 |
Why?
|
| Prospective Studies | 7 | 2016 | 203 | 0.180 |
Why?
|
| Middle Aged | 5 | 2015 | 792 | 0.180 |
Why?
|
| Perception | 2 | 2019 | 21 | 0.180 |
Why?
|
| Memory, Episodic | 2 | 2019 | 22 | 0.180 |
Why?
|
| Microglia | 3 | 2017 | 12 | 0.170 |
Why?
|
| Genetic Association Studies | 3 | 2015 | 24 | 0.170 |
Why?
|
| Mental Status Schedule | 2 | 2018 | 29 | 0.160 |
Why?
|
| Adult | 4 | 2015 | 794 | 0.160 |
Why?
|
| Independent Living | 2 | 2018 | 29 | 0.160 |
Why?
|
| Polymorphism, Genetic | 2 | 2017 | 21 | 0.150 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 9 | 0.150 |
Why?
|
| HIV Infections | 1 | 2020 | 103 | 0.150 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 32 | 0.140 |
Why?
|
| Memory, Short-Term | 1 | 2019 | 23 | 0.140 |
Why?
|
| Learning | 1 | 2018 | 20 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 9 | 0.130 |
Why?
|
| Cognitive Aging | 1 | 2018 | 27 | 0.130 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 11 | 0.130 |
Why?
|
| RNA, Messenger | 1 | 2017 | 59 | 0.130 |
Why?
|
| Gene Expression | 1 | 2017 | 45 | 0.130 |
Why?
|
| Age Factors | 4 | 2015 | 89 | 0.130 |
Why?
|
| Urinary Incontinence | 1 | 2017 | 6 | 0.130 |
Why?
|
| Phospholipase C gamma | 1 | 2017 | 2 | 0.130 |
Why?
|
| Immunity, Innate | 1 | 2017 | 7 | 0.130 |
Why?
|
| Neuropeptides | 1 | 2017 | 7 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 7 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 11 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2017 | 18 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 39 | 0.130 |
Why?
|
| Tuberous Sclerosis | 1 | 2017 | 5 | 0.130 |
Why?
|
| Arteriolosclerosis | 1 | 2016 | 4 | 0.120 |
Why?
|
| Health Literacy | 1 | 2017 | 15 | 0.120 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 34 | 0.120 |
Why?
|
| Mortality | 1 | 2016 | 13 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 13 | 0.120 |
Why?
|
| Prefrontal Cortex | 1 | 2016 | 34 | 0.120 |
Why?
|
| Awareness | 1 | 2015 | 10 | 0.110 |
Why?
|
| Heterozygote | 1 | 2015 | 48 | 0.110 |
Why?
|
| Surveys and Questionnaires | 4 | 2016 | 142 | 0.110 |
Why?
|
| Antiporters | 1 | 2015 | 4 | 0.110 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2015 | 4 | 0.110 |
Why?
|
| HLA-DRB5 Chains | 1 | 2015 | 4 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 5 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 6 | 0.110 |
Why?
|
| Cerebral Cortex | 1 | 2015 | 28 | 0.110 |
Why?
|
| Quality of Life | 1 | 2015 | 39 | 0.110 |
Why?
|
| Incidence | 4 | 2018 | 110 | 0.110 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2013 | 1 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2013 | 9 | 0.100 |
Why?
|
| Monocytes | 1 | 2013 | 7 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 147 | 0.090 |
Why?
|
| Comorbidity | 3 | 2018 | 49 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 3 | 0.070 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 4 | 0.070 |
Why?
|
| Linkage Disequilibrium | 2 | 2017 | 6 | 0.070 |
Why?
|
| Loneliness | 1 | 2007 | 20 | 0.060 |
Why?
|
| Lewy Body Disease | 2 | 2018 | 13 | 0.060 |
Why?
|
| Vitamin B 6 | 1 | 2006 | 3 | 0.060 |
Why?
|
| Vitamin B Complex | 1 | 2006 | 3 | 0.060 |
Why?
|
| Trans Fatty Acids | 1 | 2006 | 4 | 0.060 |
Why?
|
| Copper | 1 | 2006 | 11 | 0.060 |
Why?
|
| Geriatric Assessment | 2 | 2017 | 38 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2006 | 6 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2006 | 14 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 22 | 0.060 |
Why?
|
| Data Collection | 1 | 2005 | 7 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2005 | 4 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2005 | 27 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2005 | 28 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 85 | 0.050 |
Why?
|
| Chicago | 1 | 2005 | 160 | 0.050 |
Why?
|
| Biomarkers | 2 | 2016 | 101 | 0.050 |
Why?
|
| Brain Mapping | 2 | 2013 | 23 | 0.040 |
Why?
|
| United States | 2 | 2017 | 243 | 0.040 |
Why?
|
| Epistasis, Genetic | 1 | 2020 | 2 | 0.040 |
Why?
|
| Risk | 2 | 2015 | 44 | 0.040 |
Why?
|
| HIV-1 | 1 | 2020 | 59 | 0.040 |
Why?
|
| tau Proteins | 1 | 2020 | 18 | 0.040 |
Why?
|
| Community Health Planning | 1 | 2018 | 5 | 0.030 |
Why?
|
| Dementia, Vascular | 1 | 2018 | 6 | 0.030 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2017 | 8 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 8 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 10 | 0.030 |
Why?
|
| alpha-Macroglobulins | 1 | 2017 | 11 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2017 | 2 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 6 | 0.030 |
Why?
|
| Exome | 1 | 2017 | 4 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 16 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 31 | 0.030 |
Why?
|
| alpha-Synuclein | 1 | 2017 | 21 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 77 | 0.030 |
Why?
|
| Diagnosis | 1 | 2017 | 5 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 32 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 24 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 62 | 0.030 |
Why?
|
| Netrin Receptors | 1 | 2017 | 4 | 0.030 |
Why?
|
| RNA | 1 | 2017 | 8 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 16 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 19 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 39 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 51 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 41 | 0.030 |
Why?
|
| Depression | 1 | 2017 | 59 | 0.030 |
Why?
|
| Chromatin | 1 | 2016 | 5 | 0.030 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2016 | 5 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 7 | 0.030 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Endophenotypes | 1 | 2015 | 1 | 0.030 |
Why?
|
| CpG Islands | 1 | 2015 | 8 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2015 | 18 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2015 | 51 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 22 | 0.030 |
Why?
|
| Time Factors | 1 | 2015 | 208 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2014 | 11 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2013 | 17 | 0.020 |
Why?
|
| Dextrans | 1 | 2013 | 1 | 0.020 |
Why?
|
| HLA-D Antigens | 1 | 2013 | 1 | 0.020 |
Why?
|
| Thiazoles | 1 | 2013 | 1 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 8 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 75 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2013 | 7 | 0.020 |
Why?
|
| Young Adult | 1 | 2013 | 187 | 0.020 |
Why?
|
| Arterioles | 1 | 2009 | 2 | 0.020 |
Why?
|
| Cell Count | 1 | 2009 | 4 | 0.020 |
Why?
|
| Gliosis | 1 | 2009 | 4 | 0.020 |
Why?
|
| Microcirculation | 1 | 2009 | 4 | 0.020 |
Why?
|
| Encephalitis | 1 | 2009 | 4 | 0.020 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2009 | 5 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2009 | 7 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2007 | 7 | 0.020 |
Why?
|
| Social Isolation | 1 | 2007 | 8 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2006 | 9 | 0.020 |
Why?
|
| Diet | 1 | 2006 | 36 | 0.020 |
Why?
|